Kisunla (donanemab-azbt) reduced amyloid plaques in Phase III study participants by 84% after 18 months. Advertisement. Text sign showing Industry …
Lilly Treatment for Early Symptomatic Alzheimer’s Disease Approved by FDA
Share This Story, Choose Your Platform!
About the Author:
Leave A Comment